Illumina Launches TruSight Tumor 170
Illumina’s newest addition in clinical cancer research portfolio aims to establish a standardised method for tumor profiling
Illumina, Inc. has launched TruSight® Tumor 170, a 170 gene next-generation sequencing solution to support the transformation of the tumor-profiling paradigm from a series of single-gene tests to a multi-analyte approach, providing a more thorough picture of a tumor’s genomic landscape.
TruSight Tumor 170 offers an integrated DNA and RNA enrichment-based workflow,
targeting cancer-related genetic aberrations, including small variants, gene amplifications, gene fusions, and splice variants.
With optimised bioinformatics tools and automation options, laboratories can implement the assay on an in-house, research use only NextSeq® instrument. Designed to support limited nucleic acid input from formalin-fixed, paraffin-embedded (FFPE) samples, TruSight Tumor 170 facilitates efficient evaluation of biomarkers.
This new assay is poised to help realise the potential of precision oncology. By integrating DNA and RNA into one protocol, clinical researchers are able to accelerate comprehensive analysis of cancer-related variants and maximise the data obtainable from precious specimens.
Looking forward, Illumina aims to deploy the underlying assay method at the heart of TruSight Tumor 170 as a universal standard for optimised tissue assessment across a variety of applications with both fixed and customisable panels.
TruSight Tumor 170 offers broader investigational power:
• Enrichment-based assay that evaluates DNA and RNA in one integrated protocol
• 170 unique genes informed by partnering pharmaceutical companies, academic community leaders, and industry guidance
• Integrated workflow requires only 40ng of DNA and RNA from FFPE samples, allowing more comprehensive testing while preserving precious samples
• Underlying assay method to serve as a standard for optimised tissue assessment across a variety of applications